Clinical Research Directory
Browse clinical research sites, groups, and studies.
sCD163 in PBC Patients - Assessment of Disease Severity and Prognosis
Sponsor: University of Aarhus
Summary
Primary biliary cholangitis (PBC) is an autoimmune chronic liver disease, characterised by destruction of the small intrahepatic bile ducts. sCD163 is a macrophage activation marker shedded into plasma by macrophages in the liver. sMR is a soluble mannose receptor. The investigators want to investigate whether sCD163 and sMR correlate with disease severity in patients with PBC, and whether sCD163 and sMR can predict short term disease progression, changes in quality of life and death in these patients.
Official title: Macrophage Activation Marker sCD163 in PBC Patients - Assessment of Disease Severity and Prognosis
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
168
Start Date
2016-09
Completion Date
2031-09
Last Updated
2022-08-12
Healthy Volunteers
No
Interventions
Blood samples, fibroscan and questionaires
Locations (1)
Department of Hepatology and Gastroenterology, Aarhus University Hospital, Denmark
Aarhus C, Central Jutland, Denmark